Aurobindo pharma
The company’s US sales stood at $408 million compared to $470 million in March, mainly due to lower sales of the Revlimid generic. Growth during the quarter was driven by Europe and Growth Markets.
Revenue for the quarter increased by 4% from last year to ₹7,868 crore, but was below the CNBC-TV18 poll of ₹8,214 crore.Aurobindo’s Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA), margins and net profit was also significantly below the CNBC-TV18 poll, and all these parameters were lower on a year-on-year basis.
European sales increased by 18% from last year, while Growth markets grew by 9%.
OneSource
The company reported a net loss during the quarter, which was narrower than last year but most other parameters, even though they were higher year-on-year, came off sharply on a sequential basis.
Revenue increased 12% from last year but fell 23% sequentially. EBITDA more than halved from the March quarter but was up 38% from last year. Margins narrowed to 27% from 42.8% in March
SPARC
Losses continued for Sun Pharma’s research division, although they were narrower compared to the same quarter last year.
SPARC’s loss narrowed to ₹51.93 crore, down from the ₹95.85 crore loss it reported last year and the ₹60.16 crore net loss it reported in March.
Revenue for the quarter fell 43% from last year and 65% sequentially. EBITDA loss also narrowed year-on-year and quarter-on-quarter.
Sanofi India
The India unit of the MNC drugmaker also reported results on Monday, which were lower on a year-on-year basis, across parameters.
Revenue for the quarter fell 12%, EBITDA was down 18%, while margins contracted to 23.4% from 25% last year.
Sanofi follows a calendar year format for its results, which means this was their second quarter results announcement.
Aurobindo Pharma’s shares have declined 8% in the last one month, while those of OneSource, Sanofi and SPARC have declined 4%, 10% and 6% respectively during the same timeframe.
